Cosmo Pharmaceuticals N.V.

BATS-CHIXE:COPNZ Stock Report

Market Cap: CHF 1.0b

Cosmo Pharmaceuticals Valuation

Is COPNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COPNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COPNZ (CHF62.7) is trading below our estimate of fair value (CHF720.12)

Significantly Below Fair Value: COPNZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COPNZ?

Key metric: As COPNZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COPNZ. This is calculated by dividing COPNZ's market cap by their current earnings.
What is COPNZ's PE Ratio?
PE Ratio15.6x
Earnings€69.57m
Market Cap€1.08b

Price to Earnings Ratio vs Peers

How does COPNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for COPNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.8x
HIK Hikma Pharmaceuticals
19.1x12.7%UK£4.3b
ANCR Animalcare Group
32.1x15.8%UK£148.5m
EAH ECO Animal Health Group
46.2x35.6%UK£48.4m
GSK GSK
21.8x22.4%UK£54.7b
COPNZ Cosmo Pharmaceuticals
15.6x17.2%CHF 1.0b

Price-To-Earnings vs Peers: COPNZ is good value based on its Price-To-Earnings Ratio (15.6x) compared to the peer average (29.8x).

Price to Earnings Ratio vs Industry

How does COPNZ's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies12PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COPNZ is good value based on its Price-To-Earnings Ratio (15.6x) compared to the European Pharmaceuticals industry average (19.7x).

Price to Earnings Ratio vs Fair Ratio

What is COPNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COPNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.6x
Fair PE Ratio22x

Price-To-Earnings vs Fair Ratio: COPNZ is good value based on its Price-To-Earnings Ratio (15.6x) compared to the estimated Fair Price-To-Earnings Ratio (22x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COPNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 62.70
CHF 97.30
+55.2%
22.2%CHF 132.49CHF 78.92n/a4
Nov ’25CHF 68.50
CHF 97.19
+41.9%
23.0%CHF 133.30CHF 76.59n/a4
Oct ’25CHF 74.60
CHF 96.89
+29.9%
23.1%CHF 132.99CHF 76.32n/a4
Sep ’25CHF 79.20
CHF 97.14
+22.7%
22.9%CHF 132.96CHF 76.63n/a4
Aug ’25CHF 74.75
CHF 97.14
+30.0%
22.9%CHF 132.96CHF 76.63n/a4
Jul ’25CHF 71.00
CHF 93.19
+31.2%
15.2%CHF 112.82CHF 78.44n/a4
Jun ’25CHF 70.70
CHF 93.09
+31.7%
13.5%CHF 109.09CHF 79.54n/a4
May ’25CHF 73.20
CHF 93.09
+27.2%
13.5%CHF 109.09CHF 79.54n/a4
Apr ’25CHF 70.80
CHF 93.00
+31.4%
13.7%CHF 109.38CHF 79.27n/a4
Mar ’25CHF 67.00
CHF 75.96
+13.4%
10.0%CHF 83.49CHF 65.58n/a3
Feb ’25CHF 62.35
CHF 75.96
+21.8%
10.0%CHF 83.49CHF 65.58n/a3
Jan ’25CHF 50.70
CHF 73.12
+44.2%
11.3%CHF 84.75CHF 66.58n/a3
Dec ’24CHF 42.58
CHF 73.36
+72.3%
10.7%CHF 84.41CHF 67.77n/a3
Nov ’24CHF 35.10
CHF 73.97
+110.7%
10.6%CHF 85.09CHF 68.37CHF 68.503
Oct ’24CHF 39.80
CHF 73.97
+85.9%
10.6%CHF 85.09CHF 68.37CHF 74.603
Sep ’24CHF 44.40
CHF 68.10
+53.4%
17.2%CHF 85.12CHF 52.03CHF 79.204
Aug ’24CHF 44.75
CHF 74.16
+65.7%
10.1%CHF 85.55CHF 66.89CHF 74.754
Jul ’24CHF 45.50
CHF 77.41
+70.1%
7.9%CHF 85.09CHF 67.97CHF 71.004
Jun ’24CHF 46.90
CHF 80.45
+71.5%
12.9%CHF 96.55CHF 67.59CHF 70.704
May ’24CHF 54.00
CHF 80.45
+49.0%
12.9%CHF 96.55CHF 67.59CHF 73.204
Apr ’24CHF 56.80
CHF 81.83
+44.1%
12.6%CHF 97.03CHF 67.93CHF 70.804
Mar ’24CHF 60.00
CHF 81.70
+36.2%
12.8%CHF 97.22CHF 67.99CHF 67.004
Feb ’24CHF 66.80
CHF 83.59
+25.1%
12.3%CHF 99.80CHF 71.50CHF 62.354
Jan ’24CHF 61.80
CHF 83.61
+35.3%
13.7%CHF 98.40CHF 70.50CHF 50.703
Dec ’23CHF 62.40
CHF 84.07
+34.7%
16.5%CHF 97.95CHF 70.18CHF 42.582
Nov ’23CHF 56.90
CHF 85.14
+49.6%
16.1%CHF 98.81CHF 71.47CHF 35.102

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$753.98

7D

0.6%

1Y

-8.0%

Formycon

€882.8m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€50.00

7D

7.5%

1Y

-24.1%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-6.1%

1Y

3.4%